Ginkgo Bioworks (DNA) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Entera Bio (ENTX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 30.6% versus a loss of 8.7%. Over five years, ENTX leads with a -3.6% price change compared with -98.5% for DNA. Entera Bio is the larger company by market cap ($575.5 million vs $483.5 million), about 1.2 times the size, while Ginkgo Bioworks is growing revenue faster (-25.1% vs -76.8%).
Ginkgo Bioworks converts more of its revenue into profit, with a net margin of -183.8% versus -27235.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | ENTX |
|---|---|---|
| Share price | $7.46 | $3.31 |
| Market cap | $483.54M | $575.53M |
| 1-day change | -9.02% | +0.76% |
| YTD return | -10.23% | +70.36% |
| 1-year return | -8.69% | +30.63% |
| 5-year return | -98.45% | -3.64% |
| EPS (TTM) | $-4.24 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | $42.00K |
| Revenue growth (YoY) | -25.06% | -76.80% |
| Net income (latest FY) | $-312.76M | $-11.44M |
| Gross margin | — | 0.00% |
| Operating margin | -185.29% | -27450.00% |
| Net margin | -183.81% | -27235.71% |
| 52-week high | $18.22 | $4.20 |
| 52-week low | $5.37 | $0.91 |
| Distance from 52-week high | -59.06% | -21.31% |
| Analyst consensus | underperform | strong_buy |
| Avg. price target upside | +7.24% | +195.01% |
| Average volume | 2.53M | 438.35K |
| Shares outstanding | 53.94M | 174.14M |
| Employees | 485 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed DNA by 39.3 percentage points over the past year.
- Ginkgo Bioworks is more profitable, keeping -183.8 cents of every revenue dollar as net income versus -27235.7 cents for Entera Bio.
- Ginkgo Bioworks grew revenue faster in its latest fiscal year (-25.06% vs -76.80%).
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
DNA vs ENTX FAQ
Which is bigger, Ginkgo Bioworks or Entera Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $575.53M compared with $483.54M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or ENTX?
ENTX returned +30.63% over the past 12 months, compared with -8.69% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.